Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while YieldMax Universe Fund of Option Income ETFs trades at $7.63. Which is the better fit depends on your goals.
| ALNY | YMAX | |
|---|---|---|
Market Cap | $29.60B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $491.22 | $13.26 |
52-Week Low | $205.48 | $7.27 |
Enterprise Value | $27.56B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
YMAX trades at $7.63, down 1.04% today, with a bullish technical signal but bearish moving averages. The ETF maintains a consistent weekly dividend distribution schedule, though recent news highlights concerns about fee structures impacting payouts. Key resistance and support levels are clustered around $8, with the RSI indicating potential overbought conditions on a short-term basis.
The outlook is mixed; the fund's income strategy provides regular distributions, but high embedded costs and reliance on market volatility for returns present risks. Upside depends on favorable option-writing conditions, while downside is linked to market stability and expense drag.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
